HOME >> MEDICINE >> NEWS
Cancer drug proves effective in treating sickle cell disease

Researchers at the University of Illinois at Chicago College of Medicine have demonstrated that a drug long used to treat cancer is also effective in combating sickle cell disease.

The drug, called decitabine, works even in patients who don't respond to hydroxyurea, the standard treatment, and appears to produce fewer side effects.

"The results of our study are compelling," said Joseph DeSimone, professor of hematology and oncology and a member of the UIC Cancer Center. "Clearly, decitabine is an effective therapy for patients who do not benefit from the traditional treatment. It is possibly even an improvement, although more studies will have to be done."

The clinical trial was conducted at the University of Illinois Medical Center at Chicago, which houses the area's only clinic specializing in sickle cell disease. Results of the study will appear in the June 1 issue of the scientific journal Blood.

Sickle cell disease is caused by a single mutation in a gene that manufactures hemoglobin, the molecule in red blood cells that delivers oxygen to tissues throughout the body.

The defective form of hemoglobin, called hemoglobin S (for sickle), causes serious health problems. Red blood cells take on a characteristic crescent, or sickle, shape and stick to blood vessel walls.

As a result, the cells cannot squeeze through capillaries. Blood supply is blocked, depriving tissues and organs of oxygen and causing short- and long-term damage. Patients suffer episodes of intense pain, typically in the arms, legs and back, but also in the liver, kidney and abdomen.

In some severe cases, transfusions may be required because the aberrant red blood cells have a much shorter life span than normal red blood cells (10 days vs. 100) and the body can't manufacture enough new red blood cells to keep up, leading to anemia.

Patients may also suffer what is called acute chest syndrome, a particularly serious complication and th
'"/>

Contact: Sharon Butler
sbutler@uic.edu
312-355-2522
University of Illinois at Chicago
17-May-2002


Page: 1 2 3

Related medicine news :

1. Cancer in patients with hepatitis C
2. Olson family donates $1 million to Arizona Cancer Center
3. Cancer vaccines: A two-pronged attack?
4. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
5. ESMO and Imedex announce partnership for the World Congress on Gastrointestinal Cancer
6. UT Southwestern Moncrief Cancer Center is first in Texas to treat patients with TomoTherapy
7. Cancer researchers seek to predict tumor growth
8. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
9. Cancer patients in Europe unite with doctors
10. Fox Chase Cancer Center researchers identify novel target for detecting ovarian cancer in blood
11. Cancer burden seen even many years after diagnosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
Cached News: